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ABSTRACT
Background: Chordoma pathogenesis remains poorly understood. In this study, 
we aimed to evaluate the relationships between microRNA-155 (miR-155) expression 
and the clinicopathological features of chordoma patients, and to evaluate the 
functional role of miR-155 in chordoma.
Methods: The miRNA expression profiles were analyzed using miRNA 
microarray assays. Regulatory activity of miR-155 was assessed using bioinformatic 
tools. miR-155 expression levels were validated by reverse transcription-
polymerase chain reaction. The relationships between miR-155 expression and 
the clinicopathological features of chordoma patients were analyzed. Proliferative, 
migratory and invasive activities were assessed by MTT, wound healing, and Matrigel 
invasion assays, respectively.
Results: The miRNA microarray assay revealed miR-155 to be highly expressed 
and biologically active in chordoma. miR-155 expression in chordoma tissues was 
significantly elevated, and this expression correlated significantly with disease 
stage (p = 0.036) and the presence of metastasis (p = 0.035). miR-155 expression 
also correlated significantly with poor outcomes for chordoma patients (hazard ratio, 
5.32; p = 0.045). Inhibition of miR-155 expression suppressed proliferation, and the 
migratory and invasive activities of chordoma cells.
Conclusions: We have shown miR-155 expression to independently affect 
prognosis in chordoma. These results collectively indicate that miR-155 expression 
may serve not only as a prognostic marker, but also as a potential therapeutic 
target in chordoma.
INTRODUCTION
Chordoma is a rare, low-grade bone cancer arising 
from benign notochordal rests [1]. The majority of 
chordomas arise in the sacrococcygeal region, with the 
peak incidence occurring between the fifth and sixth 
decades of life. The main symptom is variable pain, which 
depends largely on tumor location. Chordoma develops 
asymptomatically with local invasion and slow growth. 
Therefore, chordomas are often diagnosed at advanced 
stages of disease [2]. Chordomas are chemo-resistant 
and relatively radio-resistant. Thus, the optimal treatment 
for chordoma is wide surgical resection, which has 
been shown to decrease local recurrence and metastasis 
[3–5]. However, it is frequently difficult to adequately 
achieve negative surgical margins because of tumor 
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location and adjacent critical vital structures. As a result, 
more than 40% of patients with chordoma experience 
local recurrence. Moreover, chordomas can metastasize 
several years after the initial diagnosis, with 10–50% 
of patients developing metastases during follow-up. 
Five- and ten-year overall survival rates were 45–77% 
and 28–50%, respectively [5]. Hence, there is an unmet 
need to explore new prognostic markers and therapeutic 
approaches for chordoma patients.
microRNAs (miRs) are small, non-coding 
RNAs which, via translation inhibition or transcript 
degradation, regulate many essential biological functions, 
including development, cell growth, cell proliferation, 
cell cycle distribution, differentiation, apoptosis, and 
metabolism [6–9]. It is noteworthy that miRs are thought 
to be involved in the regulation of 30% of the human 
genome [8]. Not surprisingly, miR dysregulation correlates 
with tumorigenesis processes in many cancers including 
chordoma [10–13], and can serve as either oncogenes or 
tumor suppressors [7].
microRNA-155 (miR-155) can act as a multifunctional 
miR, with roles in hematopoiesis, inflammation, immunity, 
viral infection, cardiovascular disease, and neoplastic 
diseases [9, 14]. miR-155 is reportedly involved in the 
tumorigenesis processes of various cancers, and its 
expression level correlates with poor outcome. However, 
there have been no reports to date implicating miR-155 in 
chordoma development.
The aims of this study were to evaluate the 
relationships between the miR-155 expression level and 
the clinicopathological features and outcomes of chordoma 
patients, and to evaluate the functional role of miR-155 
expression in a chordoma cell line. We found that miR-155 
expression independently affects prognosis in chordoma. 
Inhibition of miR-155 suppressed not only cell proliferation, 
but also migratory and invasive activities in chordoma.
RESULTS
Global miR expression and activity analysis 
suggest miR-155 is biologically active 
in chordoma
The impetus to study the role of miR-155 
in chordoma derives from miR microarray-based 
examination of two frozen clinical chordoma specimens, 
two chordoma cell lines (U-CH1 and CH8), and two 
normal human skeletal muscle samples as comparators. 
The use of skeletal muscle as a control is justified by prior 
tumor profiling studies in chordoma, and the unresolved 
question of the true chordoma cell of origin [10, 15–18]. 
In this preliminary analysis, 67 miRs were found to be 
significantly differentially expressed between chordoma 
samples (cell lines and clinical specimens) and normal 
skeletal muscle (p < 0.05; Supplementary Table S1). To 
identify those miRs most likely to be biologically active in 
chordoma, we then performed an independent analysis of 
miR regulatory activity which utilizes mRNA expression 
data in conjunction with miR target transcript prediction 
algorithms to infer the relative biological action of specific 
miRs. Using multiple miR target prediction algorithms 
(Pictar, Pita, and miRanda), miR-155 was found to have 
increased regulatory activity in chordoma samples relative 
to normal tissue (p < 0.01, false discovery rate (FDR) 
< 0.05; Supplementary Table S2). Because miR-155 was 
specifically found to have higher expression in chordoma 
tissue relative to normal (p = 0.018; Supplementary 
Table S1, S2), and its role has been characterized in other 
malignancies, we chose to further investigate its biological 
relevance in chordoma.
Overexpression of miR-155 in chordoma
miR-155 expression was measured in 23 chordoma 
tissue samples and 2 normal skeletal muscle samples 
using quantitative reverse transcription-polymerase chain 
reaction (RT-PCR). All samples expressed miR-155, with 
expression being substantially higher in chordoma tissues 
compared to the normal controls (Fig. 1A). The median 
value of miR-155 expression in chordoma tissues was 
11.3-fold that of normal tissues (Fig. 1B).
Relationships of miR-155 expression level 
with clinicopathological features of 
chordoma patients
We evaluated the relationships between  miR-
155 expression levels and clinicopathological features 
of chordoma patients including gender, age, location, 
Enneking stage, origin, the presence of local recurrence, 
and metastasis. In this analysis “primary origin” was 
defined as those patients who had never received prior 
treatment for malignant chordoma, and “recurrent origin” 
was defined as the subset of patients who presented with 
recurrent disease after surgery at an outside institution. 
Among the clinical characteristics evaluated, miR-155 
expression was significantly correlated with Enneking 
stage (p = 0.036) and the presence of metastasis 
(p = 0.035) (Table 1). Interestingly, miR-155 expression 
levels were positively correlated with disease stage in a 
step-wise manner, and there were significant differences 
between Stage 1A + 1B and both Stage 2A + 2B and 
Stage 3 (p = 0.027, p = 0.031, respectively, Fig. 2A), 
suggesting that both extent of malignant invasion, and 
degree of pathologic cellular atypia may be associated 
with aberrant miR-155 expression. Although there 
were no statistically significant differences in other 
clinicopathological features, there was a notable trend for 
higher miR-155 expression among patients with recurrent 
disease (Table 1). We also compared quantitative miR-155 
expression levels across clinical characteristics and, as 
expected, we found significant differences associated with 
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Figure 1: miR-155 is overexpressed in chordoma. A. Bar chart showing the distribution of miR-155 expression across 23 clinical 
chordoma specimens and two normal tissue controls. B. Aggregated expression levels of miR-155 in chordoma samples compared to 
normal controls.
Figure 2: miR-155 expression is correlated with stage and metastatic potential in chordoma. Dot-plots showing the 
relationships between miR-155 expression and A, B. Enneking stage, and C. the presence of metastasis. *p < 0.05.
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Enneking stage (p = 0.006) and the presence of metastasis 
(p = 0.003) (Fig. 2B, 2C, Supplementary Table S3).
Relationship between miR-155 expression 
and outcomes of chordoma patients
We next examined whether clinicopathological 
features including high and low miR-155 expression 
levels were associated with poor outcomes in 
chordoma patients. Based on Kaplan-Meier analysis 
there were significant differences between the high and 
low expression groups in overall survival (p = 0.0052, 
Fig. 3A), and metastasis-free survival (p = 0.0306, 
Fig. 3B). Because we had previously observed a 
positive correlation between miR-1 expression and 
outcome in chordoma [13], we attempted to combine it 
with miR-155 expression to improve risk stratification. 
Consistent with our hypothesis, patients with low 
Table 1: Correlation between the expression level of miR-155 with clinicopathological features
Clinicopathological features Low miR-155 High miR-155 Total P-value
Gender
 Male 9 9 18 0.692
 Female 2 3 5
Age
 ≥ 63 6 6 12 0.827
 < 62 5 6 11
Location
 Sacrum 10 10 20 0.59
 Other 1 2 3
Stage
 1A + 1B 9 4 13 0.036a
 2A + 2B + 3 2 8 10
Origin
 Primary origin 8 4 12 0.059
 Recurrent origin 3 8 11
Local recurrence
 Overall
  Yes 5 6 11 0.827
  No 6 6 12
 Primary origin
  Yes 3 0 3 0.157
  No 5 4 9
 Recurrent origin
  Yes 2 6 8 0.782
  No 1 2 3
Metastasis
 Yes 0 4 4 0.035a
 No 11 8 19
The relationships of the high and low expression group of miR-155 with clinicopathological features of chordoma patients 
were analyzed by chi-squared test.
aIndicates statistical significance. Statistical significance was defined as a P-value of < 0.05.
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miR-155 expression and high miR-1 expression had 
uniformly favorable overall survival (p = 0.0097, 
Fig. 3C) and the survival discrimination using the 
combined miR-155/miR-1 analysis appears stronger 
than that obtained by using any of the two markers 
individually. We also examined other clinical 
characteristics in our cohort, and found that, consistent 
with previous studies, the presence of metastasis 
significantly affected overall survival (p = 0.0015, 
Fig. S1A) [3–5]. In addition, although it did not 
reach statistical significance due to small sample size, 
patients with local recurrence group tended to have 
inferior outcomes compared to patients with non local 
recurrence (p = 0.0646, Fig. S1B). In a univariate 
Cox regression analysis, high miR-155 expression 
and recurrent origin were significantly associated with 
shorter overall survival of chordoma patents (hazard 
ratio, 6.35; p = 0.011, hazard ratio, 9.77; p = 0.004, 
respectively), whereas other clinicopathological 
features showed no prognostic correlations (Table 2A). 
Importantly, multivariate Cox regression revealed 
that miR-155 expression is significantly associated 
with shorter overall survival independent of recurrent 
origin (hazard ratio, 5.32; p = 0.045, Table 2B). These 
results demonstrated the miR-155 expression level to 
independently predict chordoma outcomes.
Modulating expression levels of miR-155 
in a chordoma cell line
Because of the striking association between 
miR-155 and outcome in clinical specimens, we next 
sought to examine the effects of modulating miR-155 
expression in vitro. We first performed experiments 
to prove the feasibility of miR-155 inhibition using a 
transfected antagonist. Using quantitative RT-PCR we 
found miR-155 expression levels in the U-CH1 and CH8 
cell lines to be 18.8 and 20.4-fold that of normal tissues, 
respectively (Fig. 4A). The cells were then transfected 
with a specific miR-155 inhibitor at increasing 
concentrations (10 nM, 20 nM, 40 nM, 60 nM, and 
80 nM). The miR-155 inhibitor significantly and dose-
dependently inhibited miR-155 expression in transfected 
cells, whereas the non-specific miR inhibitor transfected 
cells showed no change in miR-155 expression 
(Fig. 4B). Thus, we had established that modulation of 
miR-155 expression in vitro is feasible for downstream 
interrogation of its functional consequences.
Inhibition of miR-155 expression affects the 
proliferation of chordoma cell lines
To examine whether down-regulation of miR-155 
inhibits the growth of chordoma cells, we conducted 
Methyl thiazolyl tetrazorium (MTT) assays to evaluate 
altered in vitro proliferation. Chordoma cells were 
transfected with the miR-155 inhibitor at various 
concentrations (10 nM, 20 nM, 40 nM, 60 nM, and 
80 nM) for 24–96 h. The MTT assays revealed that 
miR-155 inhibitor transfected chordoma cells showed 
time-dependent inhibition of cellular growth at the 
concentrations tested, whereas non-specific miR inhibitor 
transfected cells and control cells continued to grow 
for the duration of the observation period (Fig. 5A). 
After transfection with miR-155 inhibitor or non-
specific miR inhibitor at a different concentration and 
incubation for 72 h, the miR-155 inhibitor transfected 
cells showed significant and dose-dependent inhibition 
of cellular growth (Fig. 5B). These results demonstrated 
Figure 3: miR-155 expression is associated with overall survival in chordoma patients. A. Kaplan-Meier analysis comparing 
overall survival between chordoma patients with miR-155 expression below the median value (↓ miR-155 group), and chordoma patients 
with at least median miR-155 expression (↑ miR-155 group). B. Kaplan-Meier analysis comparing metastasis-free survival of chordoma 
patients stratified as in (A). C. Kaplan-Meier analysis comparing overall survival of chordoma patients stratified by both miR-1 and miR-
155 expression (using median expression level cutoffs for each miRNA separately).
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Table 2: Prognostic factors for overall survival in chordoma
A) Univariate anaysis for prognostic factors of chordoma
HR 95% CI P-value
miR-155 expression (High 
or Low)a 6.35 1.54–26.29 0.011
b
Gender 0.63 0.17–2.40 0.503
Age 1.05 1.00–1.11 0.064
Location 0.61 0.13–2.83 0.524
Stage 1.63 0.71–3.73 0.250
Margin 1.41 0.92–2.15 0.116
Radiation 1.50 0.40–5.61 0.543
Origin 9.77 2.10–45.41 0.004b
B) Multivariate anaysis for prognostic factors of chordoma
miR-155 expression (High 
or Low)a 5.32 1.04–27.36 0.045
b
Origin 8.28 1.69–40.65 0.009b
aThe cut-off level was set at the median value of the miR-155 expression levels in 23 patients with chordoma.
bIndicates statistical significance. Statistical significance was defined as a P-value of < 0.05.
that down-regulation of miR-155 inhibits cell proliferation 
both dose- and time-dependently in chordoma cell lines 
in vitro.
Aberrant miR-155 expression affects the 
migratory activities of chordoma cell lines
To assess whether miR-155 inhibitor transfected 
chordoma cells show altered motility, we conducted wound 
healing assays to assess migratory activity. We observed 
the wound area at 0, 8 and 24 h after scratch injury 
(Fig. 5C). After 24 h incubation, the miR-155 inhibitor 
transfected cells covered only 46.4% of the scratch 
defect, whereas the non-specific miR inhibitor transfected 
cells covered 77.5%. The cell migratory activities were 
therefore markedly decreased in miR-155 transfected cells 
as compared with non-specific miR inhibitor transfected 
cells and control cells (p < 0.01, Fig. 5D).
Inhibition of miR-155 suppressed the invasive 
activities of chordoma cells
We next assessed whether miR-155 inhibitor 
transfected chordoma cells showed altered invasive 
activity using a matrigel invasion assay. After transfection, 
the matrigel invasion assay showed that transfection 
with the miR-155 inhibitor resulted in marked inhibition 
of the invasive activities of chordoma cells (Fig. 5E). 
The number of invasive cells among the transfected 
chordoma cells was decreased to less than 32.9% of that 
in the control chordoma cells (p < 0.01, Fig. 5F).
DISCUSSION
miRNAs are small RNA molecules which regulate 
the expression of many genes primarily at the transcript 
level, and are expressed in a highly tissue-specific manner. 
Aberrant miR expression has now been shown to affect a 
number of pathways important for cancer initiation and 
maintenance in many malignancies including chordoma. 
The dysregulated expression of several miRs including 
miR-1, miR-206, miR-31, miR-222, miR-140–3p, and 
miR-148a has been associated with chordoma in recent 
literature, however there is still a dearth of molecular 
biomarkers suitable for clinical application in this disease 
[10, 11, 13]. In this study, our effort to address this unmet 
need revealed for the first time using miR and mRNA 
microarrays and miR regulatory activity analysis that 
miR-155 expression and biological activity is significantly 
elevated in chordoma relative to normal tissues. These 
observations are consistent with recent data in other tumor 
settings showing that miR-155 can functionally act as an 
oncogene, and that its targets are involved in pathways 
regulating proliferation, apoptosis, differentiation, 
angiogenesis, and epithelial-to-mesenchymal transition 
[7, 9, 14, 19]. In addition, observed miR-155 upregulation 
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in several cancers has been associated with poor 
outcomes [20, 21]. Our study presents the first data 
demonstrating that miR-155 is upregulated in chordoma, 
and that miR-155 expression is correlated with both 
advanced disease stage and the presence of metastasis. 
Our data further show that high miR-155 expression is 
associated with shorter overall survival independent of 
other prognostic factors. Based on our prior observations 
relating miR-1 expression to outcome in chordoma, we 
also tested whether a combined model could improve 
risk stratification, and found that patients with both 
high miR-1 and low miR-155 had strikingly favorable 
outcomes, suggesting that a dual miRNA panel may 
provide even greater clinical utility.
Tumor growth, migratory, and invasive abilities 
in cancers including chordoma are required for 
initiation of the metastatic process. Recent studies 
in other malignancies have shown that miR-155 
correlates with diverse biological functions, including 
proliferation, migration and invasion, apoptosis, and 
cell cycle progression [7, 9, 14, 19]. In the present study, 
we demonstrated that controlled down-regulation of 
miR-155 expression inhibits multiple in vitro correlates 
of tumor aggression including cell proliferation, and 
both migratory and invasive abilities in chordoma. These 
data suggest that modulating miR-155 expression could 
plausibly control tumor progression, and inhibit local 
recurrence and metastasis in chordoma. Given the degree 
to which chordomas are typically refractory to standard 
therapies, miR-155 presents an exciting and novel avenue 
to potentially improve clinical outcomes.
At present, the reasons underlying miR-155-
mediated aggression in chordoma remain unclear, 
although recent data provide some interesting hypotheses. 
It has been established that each miR can interact with 
up to 200 potential target genes, making the task of 
dissecting downstream pathway aberrations challenging 
[9, 22]. However, various direct targets of miR-155 have 
been implicated in certain cancer settings. For example, 
suppressor of cytokine signaling 1 (SOCS1) and tumor 
protein 53-induced nuclear protein 1 (TP53INP1) – two 
validated targets of miR-155 –have been shown to regulate 
tumor growth, invasion, and metastasis [9]. SOCS1 does 
this via inhibition of signal transducers and activators 
of transcriptions (STAT3) [23–25]. The plausibility of 
this mechanism underlying our findings is supported by 
data implicating STAT3 up-regulation in chordoma [26]. 
Functional experiments have shown that inhibition of 
Figure 4: In vitro antagonism of miR-155 is feasible in chordoma cell lines. A. miR-155 expression levels in U-CH1 and CH8 
chordoma cell lines, and normal control tissues. B. miR-155 expression levels after transfection with miR-155 inhibitor at 10–80 nM or 
non-specific miR inhibitor at 40 nM and 60 nM. *p < 0.05, **p < 0.01 (Comparison of miR-155 inhibitor transfected cells with non-specific 
miR inhibitor transfected cells or control cells using Student’s t-test).
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miR-155 induces elevated SOCS1 expression and the 
subsequent suppression of STAT3 in various cancers 
[23–25]. In addition to SOCS1, TP53INP1, represents 
another validated target for miR-155, which is a 
proapoptotic stress-induced p53 target gene and a known 
tumor suppressor gene. According to recent literature 
overexpression of miR-155 can strongly reduce TP53INP1 
expression in cancers, and inhibition of miR-155 leads 
to the suppression of tumor growth in vitro and in vivo 
[27–29].
Studies in other cancers have also shown that 
modulation of miR-155 expression can alter proliferation 
and invasiveness [21, 25]. Upon transfection with 
miR-155 inhibitors or mimics cancer cells have shown 
marked inhibition or promotion of proliferation and 
invasion, respectively. Table 3 shows predicted direct 
targets of miR-155 in cancer, many of which are 
known regulators of pathways important for disease 
progression, including epithelial-mesenchymal transition 
(EMT), proliferation, differentiation, apoptosis, and 
angiogenesis [23, 24, 28–54]. These examples of 
validated and predicted target genes illustrate how 
modulation of miR-155 can potentially attenuate tumor 
progression via multiple mechanisms, and is therefore 
a promising target for therapeutic intervention in 
chordoma.
Figure 5: Inhibition of miR-155 decreases proliferation, migration, and invasion of chordoma cells. A, B. Cell 
proliferation assay results for U-CH1 cells transfected with miR-155 inhibitor at concentrations between 0 nM and 80 nM, and incubated 
for 24–96 h. (C, D) miR-155 antagonism resulted in the inhibition of the migratory activity of U-CH1 chordoma cells after transfection 
with either miR-155 or non-specific miR inhibitor at 40 nM. C. micrographs of chordoma U-CH1 cells at 0 h, 8 h and 24 h after wounding.  
D. The coverage rate of U-CH1 cells for each time point and condition in the wound healing assay. (E, F) Invasive activity assay results for 
U-CH1 cells transfected with miR-155 inhibitor. E. Micrographs of chordoma U-CH1 cells transfected with 40 nM miR-155 inhibitor. F. 
Average numbers of invasive chordoma cells among those transfected with 10–80 nM miR-155. *p < 0.01.
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Table 3: Predicted direct targets of miR-155 in cancer
Gene name Official name Biological functions Reported in cancer References
SOCS1 Suppressor of cytokine signaling 1
Cell proliferation, 
invasion and 
metastasis
Breast cancer, 
hepatocellular 
carcinoma, laryngeal 
squamous cell 
carcinoma, B chronic 
lymphocytic leukemia, 
colon cancer
[23], [24], [30], 
[31], [32]
TP53INP1 Tumor protein 53-induced nuclear protein 1
Cell apoptosis, 
proliferation, invasion, 
EMT, angiogenesis, 
metabolism
Brest cancer, 
pancreatic cancer [27], [28]
PPP2CA Protein phosphatase 2, catalytic subunit, alpha isozyme Cell growth Colon cancer [32]
Bcl-2 B-cell lymphoma 2 Cell apoptosis Leukemic B-cell [33]
Smad2 Mothers against decapentaplegic homolog 2
Cell migration, 
invasion, adhesion Gastric cancer [34]
Smad5 Mothers against decapentaplegic homolog 5
Cell proliferation, 
differentiation, 
apoptosis, metastasis
Lymphoma [35]
RhoA Ras homolog gene family, member A
Cell apoptosis, 
proliferation, invasion, 
EMT, angiogenesis, 
metabolism
Breast cancer [36]
Apaf-1 Apoptotic peptidase activating factor 1 Cell apoptosis Lung cancer [37]
SPI1 (PU.1) Spi-1 proto-oncogene Transcription Lymphoma [38]
C/EBPβ
CCAAT-enhancer-binding 
protein β
Cell apoptosis, 
proliferation, invasion, 
EMT, angiogenesis, 
metabolism, 
differentiation
Breast cancer [39]
VHL Von Hippel–Lindau
Cell apoptosis, 
proliferation, invasion, 
EMT, angiogenesis, 
metabolism
Breast cancer [40]
SEL1L Protein sel-1 homolog 1 Cell proliferation, apoptosis
Pancreatic ductal 
adenocarcinoma [41]
JMJD1A Jumonji domain-containing 1a A negative prognostic marker
Nasopharyngeal 
carcinoma [42]
BACH1 BTB and CNC homology 1 Cell proliferation, invasion, apoptosis
Nasopharyngeal 
carcinoma, renal 
cancer
[42], [43]
SHIP1 Src homology 2-containing inositol phosphatase-1
Proliferation, 
differentiation, 
apoptosis, metastasis
Chronic lymphocytic 
leukemia [44]
(Continued )
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Gene name Official name Biological functions Reported in cancer References
HDAC4 Histone deacetylase 4
Cell proliferation, 
differentiation, 
apoptosis, metastasis
Lymphoma [45]
PIK3R1 Phosphoinositide-3-kinase, regulatory subunit 1 (alpha)
Cell proliferation, 
differentiation, 
apoptosis, metastasis
Lymphoma [46]
APC Adenomatous polyposis coli Cell growth, proliferation, apoptosis
Papillary thyroid 
carcinoma, 
hepatocellular 
carcinoma
[47], [52]
CLDN1 Claudin 1
Cell growth, 
proliferation, 
migration, invasion
Ovarian cancer [48]
SKI Ski Cell growth, proliferation, apoptosis Melanoma [49]
CDC73 Cell division cycle 73 Cell proliferation, apoptosis
Oral squamous cell 
carcinoma [50]
FOXO3a Forkhead box O3a
Cell apoptosis, 
proliferation, invasion, 
EMT, angiogenesis, 
metabolism
Breast cancer [51]
MLH1 MutL homolog 1 Cell proliferation, apoptosis Pancreatic cancer [53]
CK1α Casein kinase-1alpha Cell proliferation, cell cycle Liposarcoma [54]
In summary, our study is the first to show that 
miR-155 expression is predictive of chordoma outcomes 
independent of other clinical factors. Additionally, our 
in vitro experiments demonstrated that inhibition of 
miR-155 suppressed cell proliferation, migratory and 
invasive activities in a chordoma cell line. Thus, our data 
suggest that miR-155 expression is not only a potential 
prognostic marker, but is also a possible therapeutic 
target in chordoma. Future studies should examine the 
feasibility of using a miR-155 antagonist with in vivo 
models, and interrogate aberrant downstream signaling 
pathway activity in chordoma which can be modulated 
therapeutically with existing small molecules.
MATERIALS AND METHODS
Human chordoma tissue samples
Samples from 23 patients who had undergone 
surgical resection of chordoma were obtained from the 
Massachusetts General Hospital (MGH) sarcoma tissue 
bank, and were studied according to the policies of the 
institutional review board of the hospital. This study was 
conducted with the approval of the MGH Institutional 
Review Board (IRB protocol #:2007-P-002464/5). 
All specimens were assessed by light microscopy and 
immunohistochemistry. The clinical characteristics of the 
chordoma patients are presented in Table 4.
RNA extraction from cell line and frozen tissue
Total RNA was extracted from the chordoma cell 
lines and chordoma tissue samples with TRIzol reagent 
(Invitrogen, CA) by the acid-guanidium-thiocyanate-phenol 
chloroform method. The total RNA quantity was determined 
using a SPECTRAmax Microplate Spectrophotometer from 
Molecular Devices (Sunnyvale, CA) at 490 nm. RNA purity 
was assessed by the ratio of absorbance at 260/280 nm.
miR and mRNA expression assays
miR expression was analyzed using miR expression 
profiling (LC Sciences, TX). 5 μg of total RNA for each 
sample was fractionated using the Microcon YM-100 
(Millipore, MA), and the small RNAs (< 300 nucleotides) 
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Table 4: Clinical characteristics of the chordoma patients
Sample 
number
Age/ 
Gender
Location Origina Stage Margin Radiation Local 
recurrent
Metastasis Follow up 
(months)
Status
1 70/M Sacrum Recurrent 1B Intraleasional margin No Yes No 165 DOD
2 71/M Sacrum Primary 1B Wide margin No No No 69 NED
3 77/M Sacrum Primary 1B Wide margin Yes No No 109 DOO
4 46/M Sacrum Primary 1B Wide margin Yes Yes No 127 AWD
5 64/M Sacrum Primary 1B Wide margin Yes No No 90 NED
6 55/M Sacrum Primary 2A Wide margin Yes Yes No 201 AWD
7 62/M Sacrum Primary 1B Wide margin Yes No No 143 NED
8 83/M Sacrum Recurrent 1B Intraleasional margin Yes Yes No 45 DOO
9 71/F L4 Primary 1B Attempted wide margin Yes No No 143 NED
10 51/F Sacrum Primary 1B Wide margin No Yes No 87 DOD
11 37/M Sacrum Recurrent 2B Wide margin No No No 128 AWD
12 74/M Sacrum Recurrent 1B Intraleasional margin Yes Yes No 69 DOD
13 58/M Sacrum Recurrent 1B Intraleasional margin No Yes No 37 DOD
14 47/M Sacrum Primary 2B Attempted wide margin Yes No No 123 NED
15 82/M Sacrum Recurrent 3 Attempted wide margin Yes Yes Yes 36 DOD
16 63/M Sacrum Primary 2A Wide margin No No No 63 NED
17 63/M Sacrum Primary 2A Wide margin No No No 63 NED
18 60/F Sacrum Primary 1A Wide margin Yes No No 61 NED
19 82/M Sacrum Recurrent 3 Attempted wide margin Yes Yes Yes 36 DOD
20 52/F L3 Recurrent 1B Wide margin Yes No No 4 DOO
21 52/F Sacrum Recurrent 2B Attempted wide margin Yes Yes No 46 DOD
22 50/M T12-L1 Recurrent 3 Attempted wide margin Yes Yes Yes 77 DOD
23 74/M Sacrum Recurrent 2B Intraleasional margin Yes No Yes 36 DOD
Abbreviations: L, lumber spine; T, thoracic spine; AWD, alive with disease; NED, no evidence of disease; DOD, dead of 
disease; DOO, dead of others.
aOrigin was defined as patient who was previously treated (recurrent origin) or not (primary origin).
were 3′-extended with a poly(A) tail by poly(A) 
polymerase. miR expression profiling was carried out 
as previously described [18]. mRNA expression levels 
for use in miR activity analysis were determined using 
GeneChip Human Genome U133A 2.0 Array (Affymetrix, 
CA) performed at the MGH Core Facility.
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miR regulatory activity analysis
miR regulatory activity analysis was performed 
using an R implementation of the regulatory effects 
scoring (RE-score) method developed by Cheng et al [55]. 
In brief, using mRNA expression data, an RE-score was 
calculated for known miRs using the average difference 
in expression of miR target transcripts and non-target 
transcripts. Target transcripts were determined by a 
user-defined choice of established miR target prediction 
algorithms including Pita, Pictar, or TargetScan [56–58]. 
mRNA data were imported into the R environment and 
miRs were determined to be significantly differentially 
activated if the RE-score was associated with a Wilcoxon 
rank sum p-value less than 0.05, and an estimated FDR 
less than 0.05. In this study, a negative RE-score indicates 
that the associated miR is more active in chordoma 
specimens than in normal tissue. The script used in this 
analysis has been uploaded as Supplementary Table S1. 
An independent gene set analysis (GSA) method was also 
employed to infer miR activity. This method used miRanda 
miR target predictions to compare expression levels of sets 
of miR targets across two phenotypes (chordoma versus 
normal). GSA for miR target gene sets was implemented 
on NCI-BRB ArrayTools [59–61].
TaqMan reverse transcription-PCR for 
quantification of miR-155
To validate miR expression levels, we performed 
quantitative RT-PCR for miR-155 (ID 002623, Applied 
Biosystems, CA) and RNU48 (ID 001006, Applied 
Biosystems, CA) using the TaqMan® MicroRNA 
Assay and the TaqMan® Universal PCR Master Mix 
(Applied Biosystems, CA), followed by evaluation 
using a StepOnePlus Real time PCR System (Applied 
Biosystems, CA) according to the manufacturer’s 
instructions. RNU48 miR was used as an endogenous 
control. The relative gene expression levels were 
calculated by the 2^ − ∆∆Ct method [62], and 
normalized by RNU48. The relative expression level 
was log10 transformed prior to analysis. All experiments 
were carried out in triplicate.
Cell lines and cell cultures
U-CH1, an established human chordoma cell 
line, was obtained from the University Hospitals of 
Ulm, Ulm, Germany [63]. Another human chordoma 
cell line, CH8, was established in our laboratory as 
previously reported [64]. These cell lines were cultured 
in RPMI1640 (Invitrogen, CA) supplemented with 
10% fetal bovine serum (FBS) and 1% penicillin/
streptomycin (Invitrogen, CA) under a humidified 
incubator of 5% CO2-95% air atmosphere at 37°C. The 
cells were passaged every 3–4 days using trypsin-EDTA 
until reaching 90% confluence.
miR-155 inhibitor and transfection
Cells were transiently transfected with 
LipofectamineTM RNAiMAX (Invitrogen, CA) according 
to the manufacturer’s instructions. The cells were 
transfected with various concentrations of miR-155 
inhibitor (Ambion®Anti-miRTM miRNA Inhibitor, TX) 
and non-specific miR inhibitor (Ambion® Anti-miRTM 
miRNA inhibitor Negative Control #1, TX) used as a 
negative control. The total RNA was harvested 48 h after 
transfection. The sequence of mature miR for miR-155 is 
5′-CUCCUACAUAUUAGCAUUAACA-3′.
MTT cell proliferation assay
Cell proliferation was evaluated by the MTT assay. 
Briefly, the cells (2 × 103 cells/well) were seeded into each 
well of four 96 well plates in antibiotic-free RPMI 1640 
supplemented with 10% FBS. The cells transfected with 
miR-155 inhibitor or non-specific miR inhibitor at various 
concentrations were incubated for 24–96 h. At a different 
time point after transfection, 20 μl of MTT (5 mg/ml, 
Sigma, MO) were added, and the plate was incubated 
at 37°C for another 4 h. In turn, the MTT formazan was 
dissolved in acid-isopropanol. Then, the reaction density 
was read at 490 nm on a SPECTRAmax Microplate 
Spectrophotometer. The MTT cell proliferation assays 
were repeated for four days. This experiment was carried 
out in triplicate.
Wound healing assay
To evaluate cell migration activity, wound 
healing assays were performed. Briefly, transfected 
cells (2 × 105 cells/well) were seeded onto the 12 well 
plates. After the cells had reached confluence, wounds 
were made by scraping with a 200 μl tip. After being 
washed 3 times in serum-free medium, the cells were 
incubated in regular medium. The wounds at 0, 8 
and 24 h were captured by a microscope (Nikon 
Instruments Inc, NY). The wound areas captured three 
images per well at different time points (10 × objective), 
and were calculated employing Image J Software. 
The coverage rate was represented by subtracting 
the wound area at each time point from the wound 
area at the 0 h time point, divided by the wound area 
at the 0 h time point.
Matrigel invasion assay
Cell invasion activity was determined by matrigel 
invasion assay using a BD BioCoatTM MatrigelTM 
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Invasion Chamber (Becton-Dickinson, MA). The 
matrigel invasion assay was performed according to 
the manufacturer’s instructions. Briefly, transfected cells 
(5 × 104 cells/ well) were seeded onto the upper chamber 
in the medium without FBS and antibiotics, and medium 
containing 10% FBS was added to the bottom chambers. 
Cell invasion was determined after 48 h of incubation. 
The invading cells were fixed using 100% methanol 
after removing non-invading cells by scrubbing from 
the upper membrane with cotton swabs, and in turn, 
stained with hematoxylin. The invading cell number 
was counted in three images per membrane under light 
microscopy (20 × objective).
Statistical analysis
The relationships between miR-155 expression 
levels and clinicopathological features of chordoma 
patients were analyzed by chi-squared test and Student’s 
t-test. Using microarray data, significantly differentially 
expressed miRs were identified by Student’s t-test. 
The miR-155 expression levels were divided by the 
median value. The high expression group was set above 
the median value, and the low expression group was set 
below the median value. Overall survival curves were 
analyzed with the Kaplan–Meier method and compared 
using the log-rank test. To verify the prognostic factors for 
overall survival, Cox proportional hazards modeling was 
performed. To detect independent prognostic factors 
in multivariate analysis, those factors with significant 
Cox regression coefficients in univariate analysis were 
selected. All statistical analyses were carried out using 
SPSS version 21.0 (SPSS Inc, IL), or the Survival package 
in R. A statistically significant difference was defined as 
p-value less than 0.05.
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